Rentschler Biopharma SE has appointed Alexander Dettmer as Chief Financial Officer, effective July 1, 2020. He will be heading the finance, supply chain management, information technology and legal functions. Mr. Dettmer succeeds Stefan Rampf, who will be leaving the company, effective June 30, 2020 to pursue a new opportunity. Mr. Dettmer brings 15 years of financial, business development and leadership experience with a focus on driving operational excellence in the healthcare and life sciences sectors. 

Dr. Frank Mathias, CEO of Rentschler Biopharma, said, “I am personally delighted to welcome Alexander to Rentschler Biopharma as he is a great addition to our team. We are impressed by his broad experience in building healthcare businesses and effectively managing change, which will be a significant asset to our company as we grow and add new services to meet the evolving needs of our clients and their patients. Alexander fully endorses our ‘Strategy 2025’ and we look forward to further bringing it to life together!”

Prior to joining the company, Mr. Dettmer held several senior leadership positions within the Fresenius SE & Co. KGaA group, which he joined in 2005. He previously served as Senior Vice President Corporate Business Development/M&A. Prior to that, he was CFO of Fresenius Kabi’s Medical Devices Division, Executive VP Finance, Procurement & HR, where his responsibilities included financial planning, controlling, compliance, strategic purchasing and product partnering. Before that, he was CFO and Managing Director at Fresenius Biotech GmbH (now: Neovii Biotech).